Search results
Results from the Health.Zone Content Network
V. ATC code J07 Vaccines is a therapeutic subgroup of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the World Health Organization (WHO) for the classification of drugs and other medical products. [1] [2] [3] Subgroup J07 is part of the anatomical group J Antiinfectives for systemic use.
The coronavirus disease 2019 (COVID-19) vaccine is important for preventing serious illness and death due to COVID-19. So far, 81.4% of people in the United States have received at least one dose ...
Vaccine. (journal) Vaccine is a peer-reviewed medical journal, published by Elsevier. It is targeted towards medical professionals who are interested in vaccinology, vaccines, and vaccination. The official journal of the Edward Jenner Society and the Japanese Society for Vaccinology, Vaccine describes itself as "an interface between academics ...
Meningococcal disease can include meningitis -- a serious, potentially life-threatening inflammation of the membranes covering the brain and spinal cord -- and/or a life-threatening blood ...
The COVID-19 vaccination program in Argentina is an ongoing effort of mass immunization. Vaccination against COVID-19 began in Argentina on 29 December 2020 aiming at health professionals. Argentina struck a deal with the United Kingdom in November 2020 for a British made vaccine produced by the pharmaceutical company AstraZeneca and the ...
Normal side effects of 4-month shots in babies include: redness or swelling where the shot was given. pain or tenderness around the shot area. irritability or fussiness. crying. sleepiness. not ...
Dose 2: age 4 months. Dose 3: age 6 months, if needed. Dose 4: Booster between ages 12 months and 15 months. Catch-up vaccine (s) after age 15 months, if needed. Haemophilus influenzae type b ...
A Cytomegalovirus vaccine is a vaccine to prevent cytomegalovirus (CMV) infection or curb virus re-activation (symptomatic flare-ups) in persons already infected. Challenges in developing a vaccine include adeptness of CMV in evading the immune system and limited animal models. [1] As of 2018 no such vaccine exists, although a number of vaccine ...